	US 11,834,675 B2
	T lymphocyte production methods and t lymphocytes produced thereby
Bitao Liang, Closter, NJ (US); Xiaohua Lu, Monmouth Junction, NJ (US); Wei Liu, Bridgewater, NJ (US); Kathy E. Karasciewicz-Mendez, Hillsborough, NJ (US); Christopher Wiwi, Basking Ridge, NJ (US); and Kruti Shah, Piscataway, NJ (US)
Assigned to CELGENE CORPORATION, Summit, NJ (US)
Appl. No. 16/067,536
Filed by CELGENE CORPORATION, Summit, NJ (US)
PCT Filed Dec. 29, 2016, PCT No. PCT/US2016/069269 § 371(c)(1), (2) Date Jun. 29, 2018, PCT Pub. No. WO2017/117418, PCT Pub. Date Jul. 6, 2017.
Claims priority of provisional application 62/272,969, filed on Dec. 30, 2015.
Prior Publication US 2021/0163890 A1, Jun. 3, 2021
Int. Cl. C12N 5/0783 (2010.01); A61K 39/00 (2006.01); A61K 35/17 (2015.01); C07K 16/28 (2006.01)

CPC C12N 5/0636 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01)]

25 Claims

1. A method of producing a cell population comprising antigen-specific T cells, comprising the steps of:

(a) isolating peripheral blood mononuclear cells (PBMCs) from a subject;

(b) culturing said PBMCs in an antigen presenting cell (APC) induction medium comprising interleukin 4 (IL-4) and soluble CD40 ligand (sCD40L) and/or comprising granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon α (IFN-α), to produce a first population of cells, wherein the first population of cells comprises T cells;

(c) culturing the first population of cells in the presence of one or more antigens, to produce a second population of cells; and

(d) culturing the second population of cells in a T cell expansion medium comprising interleukin 7 (IL-7), interleukin 15 (IL-15), and IL-4, to produce a third population of cells;

wherein the third population of cells comprises T cells that are CD3+ and are specific for an antigen added in step (c), and

wherein all of the T cells of the third population of cells that are CD3+ and are specific of the antigen added in step (c) are derived from the T cells of the first population of cells.